Trimble Inc. (NASDAQ:TRMB) shares were trading higher by 0.74 percent ($0.31) at $42.42 a piece in Monday’s session. It had closed the previous session at $42.11. TRMB trades with a P/S ratio of 4.23. This is lower than the industry’s 5.58 but higher compared with the wider sector’s 2.74. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 25.09 and a trailing 12-month price-earnings (P/E) multiple of 56.11. Shares of TRMB have uptrended 11.37% in the past three months, while the S&P 500 has moved 3.67% in that time. Trimble Inc. (TRMB) has a market cap of $10.7 billion and over the last 12 months, Trimble Inc. (NASDAQ:TRMB) has gone stronger by 47.5%. During the last 52 weeks, the (NASDAQ:TRMB) price has been as high as $43.97 and as low as $27.61. Trimble Inc. earnings have declined with an annualized rate of -2.7% over the last 5 years. The average 1-year price target for Trimble Inc. (TRMB) — averaging the work of different analysts — reveals a mean PT of $43.5/share. That’s a potential 2.55 increase relative to where Trimble Inc. (NASDAQ:TRMB) has been trading recently. The current price is seen ranging between $42.09 and $42.85. There are brokerage firms with lower targets than the average, including one setting a price target of $36.5. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $50. The collective rating of 2.1 for Trimble Inc. (NASDAQ:TRMB) also leans strongly towards the neutral end of the spectrum. Of the 14 analysts surveyed by Reuters that track TRMB 6 of them rate its stock a hold. The other 8, though not evenly; between analysts who think you should buy Trimble Inc. versus those who think you should sell it. A 8 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of TRMB or, if they already own its stock, sell it. AbbVie Inc. (ABBV) pulled off a 0.74 percent gain and now trades for $95.42. ABBV comes in with a P/S ratio of 5.59 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.36) and its peers (3.9). Also, it has an estimated price-earnings (P/E) multiple of 14.57 and a trailing 12-month price-earnings (P/E) multiple of 23.06. During the last 52 weeks, the price has been as high as $98.26 and as low as $58.75. AbbVie Inc. (NYSE:ABBV) earnings have risen with a quarterly rate of 8% over the last 5 years. Shares of ABBV have increased 30.14% in the past three monthswhile the S&P 500 has gained 22.68% in that time. AbbVie Inc. (NYSE:ABBV) has a market cap of $152.39 billion and over the last 12 months, ABBV has risen by 57.69%. The average 1-year price target for (ABBV) reveals an average price target of $99.26 per share. That’s a potential 4.02 gain from where (NYSE:ABBV) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $60. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $135. The consensus recommendation — averaging the work of 21 analysts — of 2.3 for AbbVie Inc. (ABBV) points to moderate case. Of the analysts surveyed by Reuters that track AbbVie Inc. 11 of them rate its stock a hold. The other 10 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 10 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:ABBV) or, if they already own its stock, sell it.




(adsbygoogle = window.adsbygoogle || []).push({});
